Dynamic contrast-enhanced magnetic resonance imaging of the lung reveals important pathobiology in idiopathic pulmonary fibrosis
- PMID: 34760997
- PMCID: PMC8573229
- DOI: 10.1183/23120541.00907-2020
Dynamic contrast-enhanced magnetic resonance imaging of the lung reveals important pathobiology in idiopathic pulmonary fibrosis
Abstract
Introduction: Evidence suggests that abnormalities occur in the lung microvasculature in idiopathic pulmonary fibrosis (IPF). We hypothesised that dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) could detect alterations in permeability, perfusion and extracellular extravascular volume in IPF, thus providing in vivo regional functional information not otherwise available.
Methods: Healthy controls and IPF subjects underwent DCE-MRI of the thorax using a dynamic volumetric radial sampling sequence and administration of gadoterate meglumine at a dose of 0.1 mmol·kg-1 at 2 mL·s-1. Model-free analysis of signal intensity versus time curves in regions of interest from a lower, middle and upper axial plane, a posterior coronal plane and the whole lung yielded parameters reflective of perfusion and permeability (peak enhancement and rate of contrast arrival (kwashin)) and the extracellular extravascular space (rate of contrast clearance (kwashout)). These imaging parameters were compared between IPF and healthy control subjects, and between fast/slow IPF progressors.
Results: IPF subjects (n=16, 56% male, age (range) 67.5 (60-79) years) had significantly reduced peak enhancement and slower kwashin in all measured lung regions compared to the healthy volunteers (n=17, 65% male, age (range) 58 (51-63) years) on unadjusted analyses consistent with microvascular alterations. kwashout, as a measure of the extravascular extracellular space, was significantly slower in the lower lung and posterior coronal regions in the IPF subjects consistent with an increased extravascular extracellular space. All estimates were attenuated after adjusting for age. Similar trends were observed, but only the associations with kwashin in certain lung regions remained statistically significant. Among IPF subjects, kwashout rates nearly perfectly discriminated between those with rapidly progressive disease versus those with stable/slowly progressive disease.
Conclusions: DCE-MRI detects changes in the microvasculature and extravascular extracellular space in IPF, thus providing in vivo regional functional information.
Copyright ©The authors 2021.
Conflict of interest statement
Conflict of interest: S.B. Montesi reports grants from the CHEST Foundation, the Francis Family Foundation and the National Institutes of Health during the conduct of the study; and a clinical trial agreement through their institution from United Therapeutics and Pliant Therapeutics, a research agreement through their institution from Merck, payment for clinical trial work through their institution from Promedior, royalties for writing contributions to UpToDate from Wolters Kluwer, and consulting and advisory board fees from DevPro Biopharma, outside the submitted work. Conflict of interest: I. Zhou has nothing to disclose. Conflict of interest: L.L. Liang has nothing to disclose. Conflict of interest: S.R. Digumarthy reports acting as an independent image analyst for clinical trials through their hospital for Merck, Pfizer, Bristol Mayer Squibb, Novartis, Roche, Polaris, Cascadian, Abbvie, Gradalis, Clinical Bay and Zai Laboratories; an honorarium from Siemens Medical Solutions; and a research grant from Lunit INC, all outside the submitted work. Conflict of interest: S. Mercaldo has nothing to disclose. Conflict of interest: N. Mercaldo has nothing to disclose. Conflict of interest: R.T. Seethamraju reports personal fees from Siemens Medical Solutions, USA Inc., outside the submitted work. Conflict of interest: B. Rosen has nothing to disclose. Conflict of interest: P. Caravan reports grants from National Institutes of Health during the conduct of the study; and is a founder of and holds equity in Reveal Pharmaceuticals and Collagen Medical LLC (businesses not related to this work), and unrelated research grants from Indalo Therapeutics, Pliant Therapeutics, Celgene, Pfizer and Takeda, outside the submitted work.
Figures




References
Grants and funding
LinkOut - more resources
Full Text Sources